Alkermes plc. (ALKS)
Alkermes plc. (ALKS) is a publicly-listed biopharmaceutical company focused on developing and commercializing medications for conditions in neuropsychiatry and addiction. The company operates across two core segments: established pharmaceutical products for treating serious mental illness and substance-use disorders, and a research pipeline targeting unmet medical needs in central nervous system disorders.
What the company does
Alkermes develops medications addressing conditions in neuropsychiatry and addiction. Its commercial portfolio includes medications for schizophrenia, depression, opioid addiction, and alcohol dependence. The company’s approach combines traditional small-molecule therapies with proprietary extended-release formulation technologies designed to improve patient adherence and outcomes. Its research pipeline includes candidates in development for conditions such as major depression, bipolar disorder, and other serious mental illnesses.
How it makes money
The company generates revenue primarily through product sales of its approved medications, which are marketed to healthcare systems, hospitals, and retail pharmacies. Revenue sources include sales to government programs, managed care organizations, and direct patient sales through specialty pharmacies. Alkermes also derives revenue from manufacturing services provided to other pharmaceutical companies and from licensing arrangements. The company operates a global commercial infrastructure, though much of its revenue concentration is in the US market.
Where it sits in its industry
Alkermes competes in the competitive neuropsychiatry and specialty pharma landscape alongside larger pharmaceutical corporations and other specialized biotech firms. The company differentiates itself through expertise in sustained-release formulations and a focused therapeutic approach to serious mental illness and addiction treatment. Its position is strengthened by an established commercial presence and FDA-approved marketed products, though it competes against both branded incumbents and generic alternatives in many of its therapeutic categories. The addiction and mental health treatment sectors remain fragmented, with opportunity for specialized players addressing underserved patient populations.
How to research it
Investors seeking deeper information should review Alkermes’ 10-K and 10-Q filings with the US SEC, which contain detailed financials, risk factors, competitive positioning, and development pipeline status. The company files regular regulatory updates regarding clinical trial progress, FDA approvals, and product launches. Publicly available information includes investor presentations, earnings calls, and regulatory filings disclosing pipeline advancement, revenue by product, and manufacturing or partnership developments. Medical literature and industry reports document the clinical efficacy and market positioning of its approved therapies.